|
Beurs gesloten -
Andere beurzen
|
Nabeurs 21:59:59 | |||
| 0,6980 EUR | +36,59% |
|
0,6910 | -1,00% |
| 13/07 | AB Science staakt drie klinische studies met masitinib | MT |
| 10/07 | AB Science rationaliseert portefeuille en focust op twee moleculen |  |
Belangrijkste concurrenten
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Evolutie 1 maand | Evolutie 3 maanden | Var. 1 jan | Varia. 1j. | Varia. 3j. | Varia. 5j. | Varia. 10j. | Kap.($) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +36,59% | +14,05% | -20,14% | -39,83% | -54,56% | -49,71% | -82,68% | -95,36% | -94,93% | 46,55 mln. | |
| -0,24% | +2,56% | +1,63% | +16,85% | +24,23% | +54,36% | +22,05% | +69,29% | +124,06% | 324 mld. | |
| +1,87% | +4,00% | -2,68% | +26,68% | +15,62% | +25,89% | -10,23% | -17,52% | +44,61% | 68,88 mld. | |
| -0,55% | +4,72% | +8,70% | +24,66% | +21,07% | +39,90% | +86,24% | +93,22% | +755,88% | 9,72 mld. | |
| +1,64% | +0,24% | +4,41% | +13,16% | +5,30% | +3,68% | -2,03% | -28,76% | +38,88% | 8,37 mld. | |
| +1,61% | +3,15% | -1,21% | -19,94% | -34,27% | -20,18% | -2,50% | -32,03% | - | 4,32 mld. | |
| -3,87% | +1,69% | +8,43% | -24,05% | -35,94% | -41,18% | +16,67% | +35,09% | +77,00% | 3,83 mld. | |
| +3,53% | +4,27% | +4,32% | +22,20% | +29,32% | -2,33% | +16,83% | -33,55% | - | 3,62 mld. | |
| +1,69% | -2,21% | +0,30% | -5,59% | -5,47% | +39,90% | +55,61% | +71,52% | +119,84% | 2,68 mld. | |
| +3,60% | +1,06% | +3,70% | -18,03% | -17,38% | -4,72% | -7,73% | +51,81% | - | 2,04 mld. | |
| +1,63% | +2,54% | +19,67% | -3,86% | -1,92% | -14,93% | +26,76% | -27,15% | - | 1,84 mld. | |
| +2,24% | -2,26% | +11,31% | -10,81% | -14,26% | -22,40% | -20,84% | -8,26% | -43,95% | 1,68 mld. | |
| -.--% | -.--% | - | - | - | - | - | - | - | 1,64 mld. | |
| -0,66% | -0,02% | +18,52% | +83,80% | +150,21% | +174,74% | +1.395,05% | +648,85% | - | 1,17 mld. | |
| +12,43% | +14,56% | +8,99% | -33,48% | -32,74% | +53,22% | +60,53% | +34,07% | +516,27% | 1,13 mld. | |
| +0,92% | -5,21% | -3,55% | -29,86% | -20,23% | -37,23% | -33,53% | - | - | 1,12 mld. | |
| +4,13% | -1,29% | +5,40% | +9,13% | +14,57% | +5,89% | +88,34% | +10,29% | - | 1,1 mld. | |
| +1,65% | +3,24% | +5,52% | -5,81% | -7,53% | -0,69% | +43,33% | +89,43% | +83,29% | 1,07 mld. | |
| +3,09% | -2,65% | +5,67% | -19,70% | -23,91% | -40,41% | -77,29% | -83,31% | - | 850 mln. | |
| +3,40% | +2,53% | +7,52% | -13,21% | -12,59% | -42,00% | -10,99% | -46,24% | -65,58% | 840 mln. | |
| Gemiddelde | +3,75% | -0,12% | +4,55% | -1,46% | -0,03% | +6,41% | +82,29% | +40,63% | +141,40% | 21,98 mld. | |
| Gewogen gemiddelde per kap. | +0,29% | +2,53% | +1,42% | +17,05% | +20,55% | +45,05% | +21,09% | +52,15% | +123,37% |
Kies jouw editie
Alle financiële informatie op nationaal niveau
